Literature DB >> 12534949

Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus.

Brendon Y Chua1, Anne Healy, Paul U Cameron, Owen Stock, Michael Rizkalla, Weiguang Zeng, Joseph Torresi, Lorena E Brown, Nina L Fowler, Eric J Gowans, David C Jackson.   

Abstract

The ability of antigens to elicit immune responses depends upon their initial recognition, uptake, processing and presentation by dendritic cells. This fact has been recognized by many workers and dendritic cells are now regarded as natural 'adjuvants' in the business of vaccine design. One way of persuading dendritic cells to become interested in foreign material is to decorate it with lipid moieties found in bacteria. This approach has been used in the context of synthetic peptide-based immunogens and depending on the nature of the epitopes included, can provide highly immunogenic structures capable of eliciting antibody or cytotoxic T cell responses. In this paper we describe the results of experiments in which the stimulatory effects of peptide-based vaccine candidates on human dendritic cells are examined. Our findings indicate that lipidated structures comprising vaccine target sequences of viral origin coupled to the synthetic lipid groups of bacteria are able to induce the maturation of dendritic cells, as measured by the expression of cell surface MHC class II molecules.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534949     DOI: 10.1046/j.1440-1711.2003.01133.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  5 in total

Review 1.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

2.  A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals.

Authors:  Eric J Gowans; Stuart Roberts; Kathryn Jones; Irene Dinatale; Philippe A Latour; Brendan Chua; Emily M Y Eriksson; Ruth Chin; Shuo Li; Dominic M Wall; Rosemary L Sparrow; Jude Moloney; Maureen Loudovaris; Rosemary Ffrench; H Miles Prince; Derek Hart; Weng Zeng; Joseph Torresi; Lorena E Brown; David C Jackson
Journal:  J Hepatol       Date:  2010-06-20       Impact factor: 25.083

3.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

4.  Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles.

Authors:  Yoshio Fujita; Hiroaki Taguchi
Journal:  Chem Cent J       Date:  2011-08-23       Impact factor: 4.215

Review 5.  TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease.

Authors:  Edin J Mifsud; Amabel C L Tan; David C Jackson
Journal:  Front Immunol       Date:  2014-03-03       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.